Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non-Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown.

Pore, Nabendu; Wu, Song; Standifer, Nathan; Jure-Kunkel, Maria; de Los Reyes, Melissa; Shrestha, Yashaswi; Halpin, Rebecca; Rothstein, Raymond; Mulgrew, Kathy; Blackmore, Stephen; Martin, Philip; Meekin, John; Griffin, Matthew; Bisha, Ina; Proia, Theresa A; Miragaia, Ricardo J; Herbst, Ronald; Gupta, Ashok; Abdullah, Shaad E; Raja, Rajiv; Frigault, Melanie M; Barrett, J Carl; Dennis, Phillip A; Ascierto, Maria Libera; Oberst, Michael D

Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non-Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown.

Pore, Nabendu; Wu, Song; Standifer, Nathan; Jure-Kunkel, Maria; de Los Reyes, Melissa; Shrestha, Yashaswi; Halpin, Rebecca; Rothstein, Raymond; Mulgrew, Kathy; Blackmore, Stephen; Martin, Philip; Meekin, John; Griffin, Matthew; Bisha, Ina; Proia, Theresa A; Miragaia, Ricardo J; Herbst, Ronald; Gupta, Ashok; Abdullah, Shaad E; Raja, Rajiv; Frigault, Melanie M; Barrett, J Carl; Dennis, Phillip A; Ascierto, Maria Libera; Oberst, Michael D.

Afiliación

Pore N; AstraZeneca, Gaithersburg, Maryland.
Wu S; AstraZeneca, Gaithersburg, Maryland.
Standifer N; AstraZeneca, Gaithersburg, Maryland.
Jure-Kunkel M; AstraZeneca, Gaithersburg, Maryland.
de Los Reyes M; AstraZeneca, Gaithersburg, Maryland.
Shrestha Y; AstraZeneca, Gaithersburg, Maryland.
Halpin R; AstraZeneca, Gaithersburg, Maryland.
Rothstein R; AstraZeneca, Gaithersburg, Maryland.
Mulgrew K; AstraZeneca, Gaithersburg, Maryland.
Blackmore S; AstraZeneca, Gaithersburg, Maryland.
Martin P; AstraZeneca, Gaithersburg, Maryland.
Meekin J; AstraZeneca, Gaithersburg, Maryland.
Griffin M; AstraZeneca, Waltham, Massachusetts.
Bisha I; AstraZeneca, Munich, Germany.
Proia TA; AstraZeneca, Waltham, Massachusetts.
Miragaia RJ; AstraZeneca, Cambridge, United Kingdom.
Herbst R; AstraZeneca, Gaithersburg, Maryland.
Gupta A; AstraZeneca, Gaithersburg, Maryland.
Abdullah SE; AstraZeneca, Gaithersburg, Maryland.
Raja R; AstraZeneca, Gaithersburg, Maryland.
Frigault MM; AstraZeneca, Gaithersburg, Maryland.
Barrett JC; AstraZeneca, Gaithersburg, Maryland.
Dennis PA; AstraZeneca, Gaithersburg, Maryland.
Ascierto ML; AstraZeneca, Gaithersburg, Maryland. ml.ascierto@gmailcom michael.oberst@astrazeneca.com.
Oberst MD; AstraZeneca, Gaithersburg, Maryland. ml.ascierto@gmailcom michael.oberst@astrazeneca.com.

Cancer Discov ; 11(11): 2828-2845, 2021 11.

Article en En | MEDLINE | ID: mdl-34230008

Asunto(s)

Carcinoma de Pulmón de Células no Pequeñas; Neoplasias Pulmonares; Quinasas de la Proteína-Quinasa Activada por el AMP; Anticuerpos Monoclonales; Anticuerpos Monoclonales Humanizados; Antígeno B7-H1/metabolismo; Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico; Carcinoma de Pulmón de Células no Pequeñas/genética; Carcinoma de Pulmón de Células no Pequeñas/patología; Humanos; Neoplasias Pulmonares/tratamiento farmacológico; Neoplasias Pulmonares/genética; Neoplasias Pulmonares/patología; Mutación; Proteínas Serina-Treonina Quinasas/genética; Estudios Retrospectivos; Factor de Transcripción STAT3/genética; Factor de Transcripción STAT3/metabolismo; Microambiente Tumoral

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Tipo de estudio: Observational_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Cancer Discov Año: 2021 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google